menu
    • menu
    [{"orgOrder":0,"company":"Abiogen Pharma S.p.A","sponsor":"EffRx Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"","productType":"Small molecule","year":"2023","type":"Acquisition","leadProduct":"Alendronate Sodium","moa":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Abiogen Pharma S.p.A","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Tablet, Effervescent","sponsorNew":"Abiogen Pharma S.p.A \/ Abiogen Pharma S.p.A","highestDevelopmentStatusID":"12","companyTruncated":"Abiogen Pharma S.p.A \/ Abiogen Pharma S.p.A"}]

    Find Clinical Drug Pipeline Developments & Deals by Abiogen Pharma S.p.A

    Menu

    Abiogen Pharma S.p.A

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Abiogen Pharma S.p.A

                            Italy arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Abiogen Pharma S.p.A

                            Italy arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Alendronate Sodium

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Approved

                            Recipient : EffRx Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Abiogen Pharma Completes the Acquisition of EffRx Pharmaceuticals

                            Details : Through the acquisition, Abiogen gets Effrx's Binosto (alendronate sodium), an effervescent tablet for the treatment of osteoporosis. It will allow Abiogen to continue developing on Effrx's bisphosphonates family of molecules that in the area of ​​os...

                            Brand Name : Binosto

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            May 29, 2023

                            Lead Product(s) : Alendronate Sodium

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Approved

                            Recipient : EffRx Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth